Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
about
Treatment strategies for radioactive iodine-refractory differentiated thyroid cancerSorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patientIncidence and implications of chemotherapy related hand-foot syndrome.Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologistsCharacteristics of human Ewing/PNET sarcoma models.Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib.Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenibClinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implicationsSafety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyNovel therapies in genitourinary cancer: an update.Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot studyHand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature.Sorafenib-associated hand-foot syndrome in Japanese patients.The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.Pathways and targets in hepatocellular carcinoma.Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Dermatological adverse events from BRAF inhibitors: a growing problem.Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma.Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis.Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.The adverse effects of sorafenib in patients with advanced cancers.Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.PharmGKB summary: sorafenib pathways.Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.
P2860
Q26862841-96940B68-C527-4B4F-A7FE-30D2015FC3AAQ28538514-02152CCF-F691-43F9-AAE5-9CE76838A561Q30244770-9C085702-AEFF-4214-9789-E4AE93A8B194Q30250106-22443600-99D2-4419-A238-F7D9ECCCB992Q33699635-8B148F22-FFBD-41FC-9973-F8304D5B875CQ34207858-C5560505-1997-4DAF-BE69-4C7DD7A57BA0Q34272770-0A5DD194-5551-4687-858A-520D6191A0C7Q35008659-2ED2CFEA-2D2A-41BD-A9B4-260A662ED564Q35214229-CC455395-6402-4EC6-A294-8B9A7553FD2AQ35553882-FBEF50A7-38CA-4FA1-A085-9431E72E1FB9Q35583678-A833971A-B438-4915-BEBA-BA49D98EFFE2Q35599769-5B3F7E09-8DD9-40BA-8E8C-8CC4DFBAD44CQ35640953-D1A73697-9953-4BFF-9EC3-56CFAE30F499Q35705188-A7EFFD70-C5D1-47AA-8397-2C33A0AEC70BQ35759606-3F89DF98-2E2B-48F6-A094-B8E6C5282685Q36060211-063D8556-77BF-48D5-B7F3-455758488F42Q36078348-77586C20-BCAC-4DB1-9FC7-07372CC88EFCQ36318627-C1392319-A07B-47D3-B09A-BDC98CFDF3B9Q36856612-8A4E244C-5A2C-46BE-8DB5-6D5D3121B40FQ37152133-148157C0-4FCC-40F1-9F28-12516B1A694BQ37283073-E4021190-BA16-4FA7-9142-18D5C2CCE561Q37508022-CFFD3700-7F69-44A1-8212-7487796E3BA2Q37663028-891632EC-0205-4BE1-BC1A-6AFB0D4F849CQ37845916-FACA4002-DD92-4304-9B06-57D7E2CDA25FQ37851857-8532B2DF-8344-41AC-95BE-7D013717B3CBQ37930711-04C23034-89D6-40FC-AC69-77834C1A7819Q38062022-DA047988-4A54-44C5-B954-CAD5DE2255ABQ38071132-A3FCC825-800A-4F2F-8EFF-F4FF2BD64AADQ38076349-0F7C5F86-6BF9-4F38-AE8E-6A8E62C2EAE5Q38086762-553B0E78-3A2E-44F9-87C2-F9F502EE6ECDQ38103397-CDBCA43D-6319-45E5-AD3A-AC3038A6E490Q38110320-340C840F-23F9-4FF4-86C5-16BD00C905BBQ38133409-1A360CB2-B45E-408C-98C9-64E1CC2BB27DQ38173739-6744B2AC-1B7A-49F7-82A7-6CE15B8FD3D9Q38190433-3FD1D563-98D5-4ABF-825A-977E60C5C358Q38199178-A1A3DD3C-B3B6-4423-A050-76436D286189Q38286308-FCF46E0C-7249-4054-92A5-55D57EAECD58Q38368008-ED0888BD-69DE-4572-A1A9-39FD37D7406AQ38864682-5ABD77DC-E584-4FC3-AC16-F22E9CC3475BQ39474625-C5AD1CA1-8D09-4E67-8097-D0098E4A89A3
P2860
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
@en
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
@nl
type
label
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
@en
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
@nl
prefLabel
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
@en
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
@nl
P2093
P2860
P1433
P1476
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
@en
P2093
Mario E Lacouture
Shenhong Wu
Triantafillos Fillos
P2860
P304
P356
10.1080/02841860701765675
P577
2008-01-01T00:00:00Z